Brief: Cortexyme Inc - Preliminary, Unaudited 2021 Year-End Cash, Cash Equivalents, And Investments Of $126.7 Million Allows For Strategic Flexibility

IRulya Therapeutics

01/02/2022 13:52

Feb 1 (Reuters) - Cortexyme Inc  CRTX.O :
    * CORTEXYME INC - PRELIMINARY, UNAUDITED 2021 YEAR-END CASH,
CASH
EQUIVALENTS, AND INVESTMENTS OF $126.7 MILLION ALLOWS FOR
STRATEGIC FLEXIBILITY
    * CORTEXYME - COR588 CURRENTLY COMPLETING PHASE 1 SAD/MAD
TRIAL IN
COHORT OF HEALTHY PARTICIPANTS IN AUSTRALIA WITH STUDY RESULTS
EXPECTED IN Q2 OF 2022
    * CORTEXYME - NEXT GENERATION LYSINE GINGIPAIN INHIBITOR
COR588
WITH NOVEL STRUCTURE, IMPROVED PHARMACOLOGIC, SAFETY PROFILE
PRIORITIZED FOR ALZHEIMER'S DEVELOPMENT

Source text for Eikon:  ID:nBw1ZQyZ4a 
Further company coverage:  CRTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))